Product Description
Piperacillin and tazobactam combination injection is used to treat bacterial infections in many different parts of the body (eg, stomach or bowel, lungs, skin, female reproductive organs). (Sourced from: https://www.mayoclinic.org/drugs-supplements/piperacillin-and-tazobactam-intravenous-route/description/drg-20072716)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Chile, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Influenza, Human|Pneumonia
Phase 2: Bacteremia|Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Coinfection|Community-Acquired Infections|Pseudomonas Infections|Pyelonephritis|Respiratory Tract Infections|Urinary Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| REMAP-CAP | P3 |
Recruiting |
COVID-19|Pneumonia|Influenza, Human |
2026-02-01 |
2024-11-27 |
||
| NCT04673175 | P2 |
Recruiting |
Pneumonia|Bacteremia|Pseudomonas Infections |
2025-12-31 |
12% |
2024-08-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| FRENCH24 ANIS | P3 |
Active, not recruiting |
Unknown |
2025-04-03 |
|||
| MK-7625A-036 | P1 |
Completed |
Pneumonia |
2024-09-14 |
88% |
2024-09-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| MK-7625A-036 | P1 |
Completed |
Pneumonia |
2024-05-30 |
88% |
2025-05-02 |
Treatments |
| CEFTOREA | P3 |
Active, not recruiting |
Pneumonia |
2021-07-25 |
2022-03-13 |
Treatments |
|
| CTR20132616 | P2 |
Recruiting |
Urinary Tract Infections|Respiratory Tract Infections |
None |
2025-04-29 |
Treatments |
|
| CTR20130999 | P2 |
Active, not recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| CTR20130987 | P2 |
Recruiting |
Urinary Tract Infections|Respiratory Tract Infections |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| CTR20132852 | P2 |
Active, not recruiting |
Urinary Tract Infections|Chronic Obstructive Pulmonary Disease|Pyelonephritis|Bronchiectasis|Respiratory Tract Infections|Bronchitis, Chronic|Community-Acquired Infections|Pneumonia|Coinfection |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/24/2025 |
News Article |
Merck Announces First-Quarter 2025 Financial Results |
|
04/10/2025 |
News Article |
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients |
|
04/09/2025 |
News Article |
B. Braun Medical Inc. Announces US FDA Approval of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection in the DUPLEX® Drug Delivery System |
|
03/17/2025 |
News Article |
Avenacy Announces Launch of Five Injectable Antibiotic Products in the U.S. Market |